AbCellera Biologics (ABCL)
(Delayed Data from NSDQ)
$3.83 USD
-0.12 (-3.04%)
Updated May 10, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
ABCL 3.83 -0.12(-3.04%)
Will ABCL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ABCL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABCL
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ABCL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates
Other News for ABCL
3 Stock Gems Hiding in the Nasdaq
5 Of 7 AI Categories Rose, Slightly, Over Past Week
5 Of 7 AI Categories Rose, Slightly,Over Past Week
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
Buy Rating Affirmed for AbCellera Biologics on Strong Financials and Promising Partnerships